
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a financially sound company with strong product offerings, including TrueMRD and Percepta, and established partnerships. With a focus on R&D and expansion in key markets, such as urology, endocrinology, and breast cancer, there is potential for growth. While facing some competition and legal challenges, the company's evidence-based products and strong financial position make them a promising investment opportunity.
Bears say
Veracyte is a genomic diagnostics company with a negative outlook due to potential market saturation for its Afirma test and increased competition in the urology diagnostics market. While the company has a strong margin base and cash generation potential, future investments may limit margin expansion. Veracyte also faces risks related to reimbursement and payer concentration, as well as potential legal litigation. However, the company has potential upside drivers in the form of sales growth from its Decipher and Afirma tests, as well as the potential for increased cash flow.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares